Skip to content

MDMA: all studies

Page 46 of 347: studies 451 to 460 of 3,461, newest first. Back to the MDMA overview

Research

Cerebrospinal Fluid Serotonin level as Biomarker for Neurotoxicity after 3,4-Methylenedioxymethamphetamine (MDMA)

Research Journal of Pharmacy and Technology August 30, 2022 Fatin H. Zakaria, Samhani Ismail, N.M.J Khadijah

A persistent 3,4-Methylenedioxymethamphetamine (MDMA) exposure may disrupt the human body serotonergic system which subsequently leads to physical and psychiatric chaos. Serotonin, a well-known monoamine neurotransmitter which is the main target of MDMA can be found in cerebrospinal (CSF) fluid. Its variation reflects the severity of neuronal damage caused by MDMA exposure. Hence, this article...

Dantrolene Administration in the Management of the Prehospital Patient with Methylenedioxymethamphetamine Overdose: A Case Series and Literature Review.

Case Reports in Critical Care August 27, 2022 Kia Nikoomanesh, Alexander T Phan, Julian Choi et al.

Methylenedioxymethamphetamine (MDMA) is a psychoactive substance that is used commonly as a recreational drug at rave music festivals. MDMA intoxication can cause a myriad of symptoms and side effects including the manifestation of hyperpyrexia in patients. Hyperpyrexia can mimic a heat stroke and ultimately lead to various forms of end-organ damage. The most common methods used in treating...

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review

Journal of Psychopharmacology August 26, 2022 Joost J. Breeksema, Bouwe Kuin, Jeanine Kamphuis et al. 171 citations

Introduction: Small-scale clinical studies with psychedelic drugs have shown promising results for the treatment of several mental disorders. Before psychedelics become registered medicines, it is important to know the full range of adverse events (AEs) for making balanced treatment decisions. Objective: To systematically review the presence of AEs during and after administration of...

Community-led guerrilla drug checking in response to deaths from adulterated MDMA in Victoria, Australia

Drugs, Habits and Social Policy August 17, 2022 Monica J Barratt, Stephen Bright, Ash R. Blackwell

Purpose Following deaths and hospitalisations in Melbourne, Victoria, Australia, related to the unwitting consumption of a combination of 25C-NBOMe and 4-FA, a community-led unauthorised drug checking service was rapidly established at a subsequent music festival. We aim to demonstrate the value of community-led drug checking, even when conducted in less-than-ideal conditions, by describing...

Adolescent and adult time trends in US hallucinogen use, 2002–19: any use, and use of ecstasy, LSD and PCP

Addiction August 17, 2022 Ofir Livne, Dvora Shmulewitz, Claire A Walsh et al. 90 citations

Abstract Background and Aims Hallucinogen use is potentially harmful. Information on whether such use has increased in recent decades is lacking. This study assessed overall and age‐specific time trends in the prevalence of 12‐month hallucinogen use in the US general population. Design Cross‐sectional. Setting Data from the US National Survey on Drug Use and Health, 2002–19. Participants...

Ecstasy in Classic Christian Mysticism

Zenodo (CERN European Organization for Nuclear Research) August 1, 2022 Bernard Mcginn preprint

Ecstasy (literally, ‘standing outside’), that is, the sense of being outside or beyond the ordinary modes of consciousness, seems to be a universal trait of human existence. Among the many forms of ecstasy is religious, or ‘supra-normal’, ecstasy, which is seen as coming from the action of a higher source, or divinity. This essay examines the forms of religious ecstasy and related terminology...

Effects of 3,4-Methylenedioxymethamphetamine on Conditioned Fear Extinction and Retention in a Crossover Study in Healthy Subjects

Frontiers in Pharmacology July 13, 2022 Patrick Vizeli, Isabelle Straumann, Urs Duthaler et al. 43 citations

Background: 3,4-Methylenedioxymethamphetamine (MDMA) has shown initial promise as an adjunct in psychotherapy to treat posttraumatic stress disorder (PTSD). Its efficacy and safety have been demonstrated across phase I–III studies. However, the mechanism underlying the potential utility of MDMA to treat PTSD in humans has not yet been thoroughly investigated. Preliminary evidence suggests that...

DOI: 10.3389/fphar.2022.906639 (opens in new tab) Full text (opens in new tab) Fear extinction Skin conductance response Fear-potentiated startle Oxytocin +1

Methylenedioxymethamphetamine (MDMA)-Assisted Therapy in Hawaii: A Brief Review

Cureus June 28, 2022 Ann M. Inouye, Aaron Wolfgang 5 citations

The Food and Drug Administration (FDA) granted breakthrough therapy status to 3,4-methyl​enedioxy​methamphetamine-assisted therapy (MDMA-AT) in 2017 due to preliminary evidence supporting its efficacy and safety in treating post-traumatic stress disorder (PTSD). A series of six phase-II clinical trials studying MDMA-AT for treatment-resistant PTSD found that 54% of MDMA-AT full-dose...

Amitriptyline Accelerates SERT Binding Recovery in a Rat 3,4-Methylenedioxymethamphetamine (MDMA) Model: In Vivo 4-[18F]-ADAM PET Imaging

International Journal of Molecular Sciences June 24, 2022 Chi-Jung Tsai, Chuang-Hsin Chiu, Yu-Yeh Kuo et al.

Numerous studies have confirmed that 3,4-Methylenedioxymethamphetamine (MDMA) produces long-lasting changes to the density of the serotonin reuptake transporter (SERT). Amitriptyline (AMI) has been shown to exert neuroprotective properties in neuropathologic injury. Here, we used a SERT-specific radionuclide, 4-[18F]-ADAM, to assess the longitudinal alterations in SERT binding and evaluate the...

MDMA-assisted therapy for posttraumatic stress disorder: A pooled analysis of ethnoracial differences in efficacy and safety from two Phase 2 open-label lead-in trials and a Phase 3 randomized, blinded placebo-controlled trial

Journal of Psychopharmacology June 21, 2022 Terence H. W. Ching, Monnica T. Williams, Julie B. Wang et al. 29 citations

Background: Limited ethnoracial diversity in previous ±3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) trials for posttraumatic stress disorder (PTSD) has prompted questions concerning whether Black, Indigenous, and People of Color (BIPOC) also benefit from this treatment. Methods: Secondary analysis was conducted using a modified intent-to-treat sample pooled from two Phase 2...